ArticlePatient preference and adherence2026
Health-Related Quality of Life Among Patients with Treatment-Resistant Schizophrenia Receiving Clozapine-Based Therapy in South Kalimantan, Indonesia.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Treatment-resistant schizophrenia (TRS) is associated with impairment and reduced health-related quality of life (HRQoL). Although clozapine is the standard treatment for TRS, evidence regarding HRQoL across clozapine-based regimens in low- and middle-income settings remains limited. This study evaluated HRQoL among clinically stable outpatients with TRS receiving clozapine-based therapy in Indonesia. Methods: A cross-sectional study was conducted at the mental hospital between November 2024 and January 2025. Participants (n = 147) received clozapine as monotherapy or in combination with first-generation antipsychotics (FGAs), second-generation antipsychotics (SGAs), or both. HRQoL was assessed using the Indonesian EQ-5D-5L and EQ-VAS. Differences across regimens were assessed using the Kruskal-Wallis test, followed by Mann-Whitney U pairwise comparisons with Bonferroni correction. Spearman's rank correlation assessed the association between EQ-5D-5L utility and EQ-VAS. Adjusted general linear models examined associations between treatment regimen and HRQoL after accounting for sociodemographic and characteristics. Results: Mean EQ-5D-5L utility and EQ-VAS scores were 0.804 ± 0.10 and 73.64 ± 9.46. Mobility was the least affected domain (95.2% reporting no problems), whereas impairment was observed in usual activities and anxiety/depression. EQ-5D-5L utility was positively correlated with EQ-VAS (Spearman's Conclusion: Clinically stable outpatients with TRS receiving clozapine-based therapy demonstrated favorable HRQoL, although impairments persisted in psychological well-being and daily functioning. Treatment regimen remained associated with both HRQoL measures after adjustment. These findings represent associations rather than causal effects and support individualized treatment selection, monitoring of treatment burden, and integration of psychosocial interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.